| ORIGINAL ARTICLE |
|
| Year : 2022 | Volume
: 42
| Issue : 2 | Page : 72-80 |
|
|
Plasminogen activator inhibitor-1 and circulating ceruloplasmin levels in men with iron-deficiency anemia and heart failure with concomitant prostate cancer and their dynamics after treatment
Olexandr Kuryata1, Oksana Sirenko1, Artem Tykhomyrov2, Tetyana Yatsenko2
1 Department of Internal Medicine 2, State Establishment “Dnipropetrovsk Medical Academy of Health Ministry of Ukraine,” Dnipro, Ukraine
2 Department of Chemistry and Biochemistry of Enzymes, Palladin Institute of Biochemistry, NAS of Ukraine, Kyiv, Ukraine
Correspondence Address:
Dr. Oksana Sirenko
Vernadsky Str. 9, Vernadsky Str. Dnipro, 49044
Ukraine
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jmedsci.jmedsci_427_20
|
|
|
Background: The aim was to determine the activity of plasminogen activator inhibitor-1 (PAI-1) and levels of circulating ceruloplasmin (CP) in men with iron-deficiency (ID) anemia and heart failure with preserved ejection fraction (HFpEF) with concomitant prostate cancer and their dynamics after intravenous iron hydroxide sucrose supplementation. Methods: Dynamic observation and treatment was performed in 53 men with ID anemia and HFpEF with concomitant prostate adenocarcinoma. Serum PAI-1 activity levels were determined using a modified colorimetric method of tissue-type plasminogen activator determination. Serum CP levels were evaluated by immunoblot assay. Results: After 10 days of treatment in the group of patients treated with intravenous iron (III) hydroxide sucrose, the median PAI-1 activity level decreased by 9.2% (P < 0.001), in Group II, this indicator was not significantly different. After 10 days of treatment, it was estimated decreased median CP level by 35% (P < 0.001), in comparison with standard therapy – on 14.4% (P < 0.001). Conclusion: The infusion of intravenous iron (III) hydroxide sucrose in men with ID anemia and HFpEF with concomitant prostate cancer contributed to a significant decrease of PAI-1 activity level and CP level.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
